Sunshine Biopharma Inc.: Sunshine Biopharma's Coronavirus Treatment Anticipated to Be Effective Against the New Variant Identified in the UK

(1)
MONTREAL, QC / ACCESSWIRE / December 22, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that its Anti-Coronavirus drug development program is unaffected by the recent discovery of a new strain of Coronavirus in Southern England. The new strain appears to be more easily transmissible due to a mutation in the Spike Protein, the crown-like structure on the surface of the virus which allows it to gain entry into the host cell. Sunshine Biopharma's Anti-Coronavirus compound, SBFM-PL4, acts on the Coronavirus Papain-Like Protease (PLpro) which is a non-structural protein encoded by the viral genome and synthesized by the hijacked protein synthesis machinery of the host cell. Sunshine Biopharma's SBFM-PL4 inhibits PLpro and arrests viral replication. SBFM-PL4 is expected to inhibit the PLpro of the UK variant just as well as it does the original strain since the UK strain does not show any mutations in the PLpro gene.

Related Keywords

United Kingdom ,Montreal ,Quebec ,Canada ,Kostenloser Wertpapierhandel ,Steven Slilaty ,Camille Sebaaly ,Exchange Commission ,Sunshine Biopharma Inc ,Mcgill University Jewish ,Sunshine Biopharma ,Spike Protein ,Coronavirus Papain Like Protease ,Acute Respiratory ,Multidrug Resistant Cancer Cells ,Pancreatic Cancer ,Small Cell Lung Cancer ,Breast Cancer ,Uterine Sarcoma ,Mcgill University ,Jewish General Hospital ,Additional Information ,ஒன்றுபட்டது கிஂக்டம் ,மான்ட்ரியல் ,க்வீபெக் ,கனடா ,பரிமாற்றம் தரகு ,மகில் பல்கலைக்கழகம் நகை ,ஸ்பைக் ப்ரோடீந் ,எடுப்போசை சுவாச ,கணையம் புற்றுநோய் ,சிறிய செல் நுரையீரல் புற்றுநோய் ,மார்பக புற்றுநோய் ,கருப்பை சர்கோமா ,மகில் பல்கலைக்கழகம் ,நகை ஜநரல் மருத்துவமனை ,